Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001126 · ClinicalTrials.gov registry record · Phase 1
Treatment With Cidofovir for Children With Laryngeal Papillomatosis (Warts in the Throat)
A Phase 1 study of Papilloma, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT00001126: Completed Phase 1 study of Papilloma, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00001126 is a Phase 1 study of Papilloma that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 36 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001126, a Phase 1 study of Papilloma, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see what dose of the drug cidofovir is safe to treat laryngeal papillomatosis (warts in the throat which occur over and over) in children. Laryngeal papillomatosis is caused by infection with a virus called human papillomavirus (HPV). At present, there is no approved drug to treat this infection. However, cidofovir is a drug effective against several viruses. Cidofovir may be able to attack the HPV virus. This study tests the safety of giving this drug to children.
Conditions Studied
Interventions
- DRUG Cidofovir
Study Locations (1)
Alabama
- NIAID/DMID/CASG Central Unit - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Est. Completion | 2005-11 |
| Phase | Phase 1 |
What the finished NCT00001126 record still lists
NCT00001126 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower).
The record links to 1 condition, with Papilloma appearing as the primary indexed condition, and to 1 intervention - of which Cidofovir is the first listed.
NCT00001126 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT00001126 about?
NCT00001126 is a clinical study titled "Treatment With Cidofovir for Children With Laryngeal Papillomatosis (Warts in the Throat)". The purpose of this study is to see what dose of the drug cidofovir is safe to treat laryngeal papillomatosis (warts in the throat which occur over and over) in children. Laryngeal papillomatosis is caused by infection with a virus called human papillomavirus (HPV). At present, there is no approved...
What is the current status of trial NCT00001126?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. Estimated completion is 2005-11.
What conditions does trial NCT00001126 study?
This clinical trial studies the following conditions: Papilloma.
What interventions are being tested in trial NCT00001126?
The interventions under investigation include: Cidofovir (DRUG).
Who is sponsoring clinical trial NCT00001126?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001126 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Papilloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00001126's enrollment target sits among peer trials
36 1210th of 2000 higher than 743 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer